Research programme

Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel strategies to overcome these, provide proof of principal for phase I/II trial, and thus impact on MM-patient’s survival. Currently-used drugs target both MM cells (MMC) and cells of the bone marrow (BM) microenvironment or ‘niche’ that are critical for supporting MMC survival, proliferation and growth. Since patients repeatedly relapse after such treatments, the following mechanisms of relapse are considered and need to be investigated:


i) drugs have spared specific subclones or subpopulations of MMC


ii) drugs induce alterations in cells of the ‘niche’ that promote drug-resistance.


OVER-MYR integrates a network of outstanding researchers from 6 EU countries with internationally recognized experience in clinics and human and animal models of MM, who will jointly reach their objectives through complementary and interactive workpackages (WPs).

Overmyr © 2012